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Summary.-Fragments of human renal carcinoma tissue have been co-cultured with
mouse calvaria. In 9/13 cases significant bone resorption occurred whilst in no case
did control kidney cause significant resorption. When bone resorption did occur, it
could be reduced by inclusion of indomethacin in the culture medium. In some cases
when theophylline was included in culture medium to prevent cyclic AMP breakdown,
there was enhancement of tumour-induced bone resorption. Control studies without
tumour showed that none of the experimental treatments had a direct effect on bone.
Radioimmunoassay of prostaglandin E (PGE) levels in pooled culture media showed
that tumour fragments produced appreciable amounts of PGE, and that this produc-
tion was lowered by indomethacin and increased by theophylline. It is concluded that
the bone resorption induced by these tumours is due to a prostaglandin, and that
prostaglandin production may be controlled by changes in cyclic AMP metabolism.
ADVERSE metabolic effects are fre-
quently associated with both primary and
metastatic neoplastic disease, often due to
the production by the tumour of a
humoral agent (Rees, 1976). Amongst
these effects is hypercalcaemia due to the
production by neoplastic tissue of bone-
resorbing agents, especially when the
tumour readily metastasizes to bone.
In the case of renal carcinoma there is
a known incidence of hypercalcaemia and
also a propensity of the tumour to meta-
stasize to bone (Heath, 1976). Previously
it has been shown that the hypercalcaemia
may be associated with ectopic para-
thyroid hormone (PTH) production
(Greenberg, Martin and Sutcliffe, 1973) or
with prostaglandin (PG) production
(Brereton et al., 1974; Robertson et al.,
1975).
This paper demonstrates the production
of bone-resorbing activity by unselected
renal carcinomas in tissue culture, and
presents evidence that a PG may be a
major causative agent.
MATERIALS AND METHODS
Materials. BGJ culture medium (Biggers,
Gwatkin and Heynor, 1961) was prepared as a
powder. The final solution was suppleniented
with antibiotics, an antifungal agent, ascorbic
acid (150 ,ug/ml) and 15% heated horse serum
as described previously (Webster, Atkins and
Peacock, 1974).
The PTH used was partially purified bovine
hormone with a potency of 1000 u/mg
(Moseley et al., 1975), 1,25-dihydroxychole-
calciferol (1,95-(OH)2D3) was the gift of
Roche Products Ltd, Welwyn Garden City,
and prostaglandin E2 (PGE2) the gift of
Dr J. E. Pike, Upjohn Co., Kalamazoo,
U.S.A. All other chemicals wfere obtained
from standard suppliers.
Calvaria, for use in bone culture, were
obtained from 5-7-day-old Swiss Albino
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mice bred in our own colony. Control and
tumour tissue was obtained unselectively
from patients undergoing nephrectomy for
renal cortical carcinoma. All the patients were
normocalcaemic; histological examination
confirmed the diagnosis in all cases. Tissue,
as soon as possible after excision, was placed
in ice-cold culture medium for transportation
to the laboratory. Explants of material were
normally placed in culture within 1-5 h of
excision.
Methods.-The bone culture method has
been described in detail elsewhere (Webster
et al., 1974). Briefly, calvaria were explanted
and equilibrated in bulk in 40 ml culture
medium for 12-24 h at 37°C in an atmosphere
of 5% CO2 in air. After the equilibration
period, calvaria were transferred to small
culture dishes containing 2 ml of medium.
Incubations were then continued for 3 days,
at the end of which time the calcium level in
the medium was measured by automatic
titration using a Corning Model 503 Calcium
Analyser.
In co-culture experiments calvaria were
placed on the stainless steel grid as usual and
surrounded by 4 1-mm3 explants of control
or tumour renal tissue. Care was taken to
ensure that there was no direct contact
between the bone and other tissues. Viability
of the explanted renal tissue was assessed by
histological examination of the tissue before
and after culture. Tissue morphology was
preserved with little overt evidence of cell
death, thus minimizing the possibility that
bone resorption might be produced by com-
ponents of disintegrating cells.
In experiments where 1,25-(OH)2D3, PGE2,
theophylline or indomethacin were added to
culture media, they were dissolved in a small
amount of ethanol and added to the medium
to give a level ofnot more than0-4% ethanol.
This level of ethanol has been shown pre-
viously not to affect the response of bone to
PTH (Atkins et al., 1972). Results were
expressed as the release of ,umol calcium
during the 3-day incubation period. Differ-
ences were assessed by means of Student's
t test; values ofP < 0-05 were assumed to be
significant.
PGE levels were assessed by radioimmuno-
assay after extraction and purification of
pooled media on columns of silicic acid
(Hillier and Dilley, 1974). Recovery of added
3H-PGE2 was 53-6 ± 2-2% (n = 29). The
antiserum used did not distinguish between
PGE1 and PGE2, and levels are therefore
expressed as total PGE (ng/ml) corrected for
recovery after silicic acid chromatography.
PTH levels were measured by radioimmuno-
assay (Melick and Martin, 1968) using anti-
serum BW 211/32 (Burroughs Wellcome) and
highly purified bovine PTH for labelling and
as standard, and cyclic AMP levels were
assessed by a specific protein-binding assay
(Brown et al., 1971).
RESULTS
Control experiments
In order to identify the nature of any
bone-resorbing factors produced by tu-
mours, it was necessary to ensure that
pharmacological manipulation of the
system had effects on tumour cells rather
than on bone tissue. The effects of PTH
in this bone culture system are well
known (Webster et al., 1974) and PTH-
induced bone resorption can be prevented
by a variety ofphysiological and pharma-
cological agents (Atkins and Peacock,
1975). Many of these inhibitors also
inhibit bone resorption induced by other
agents such as 1,25-(OH)2D3 (D. Atkins,
unpublished observations).
Fig. 1. shows that PGE2 is a potent
bone-resorbing agent, the minimum effec-
tive dose being 10 ng/ml. Table I shows
that bone resorption, however induced,
was not inhibited by concentrations of
indomethacin which are reported to in-
hibit prostaglandin biosynthesis (Flower,
1974).
Another sudy has shown (Martin et al.,
1976) that membrane adenylate cyclase
activity is elevated in renal cortical
carcinoma. An attempt was therefore
made to reduce adenosine-3',5'-cyclic
monophosphate (cyclic AMP) hydrolysis
by including a phosphodiesterase (PDE)
inhibitor (theophylline) in culture media.
Levels of theophylline generally used to
inhibit PDE (10 mM) are toxic to bone
(J. N. M. Heersche, personal communica-
tion). However, lower levels (up to 2 mM)
did not stimulate bone resorption, nor did
they modify the responsiveness to PTH
(Table II). At the higher dose levels there
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TABLE I.-The Effect of Indomethacin on Bone Resorption in Culture
Exp. 1. PTH
PTH (1 u/ml)
PTH+7 0 x 10-6M indomethacin
PTH+1 *4x 10-5M indomethacin
PTH+2 8 x 10-5M indomethacin
Exp. 2. 1,25-(OH)2D3
1,25-(OH)2D3 (10 ng/ml)
1,25-(OH)2D3+ 7 x 10-6M indomethacin
1,25-(OH)2D3+1 4 x 10-5M indomethacin
1,25-(OH)2D3+2 8 X 10-5M indomethacin
Exp. 3. PGE2
PGE2 (4 ,ug/ml)
PGE2+ 7 x 10-6M indomethacin
PGE2+1-4 x 10-5M indomethacin
PGE2+2*8 x 10-5M indomethacin
Calcium release
,umol/3 days
1 59±0*18
1 13±0-15
1*30±0*14
1*20±0*18
1 13±0*16
1*02±0*23
1 09±0 19
0-98±0-23
1 *20±0- 12
1 00±0 14
1*10±0-13
1*00±0*12
Calcium release is expressed as the mean difference from the control ± s.e. (n = 10). In no case were the values for indomethacin-treated bone significantly different from those treated with resorbing agent alone.
TABLE II.-The Effect ofTheophylline on Bone Resorption in Culture
Exp. 1
Theophylline 2 *5 X 10-4M
Theophylline 5 X 10-4M
Theophylline 1 x 10-3M
Theophylline 2 x 10-3M
PTH 0 5 u/ml
Exp. 2
PTH 0 3 u/ml
PTH 0 03 u/nl
PTH 0 03 u/mi
+10-3M theophylline
10-3M theophylline
Calcium release
(,umol/3 days)
0-15IO-09
0-46±0- 13
-0 04±0 * 14
-0 49±0-05
0-91±0-17
0-68±0-21
0*14±0-32
0 31± 0-22
0 * 10+0* 23
Results expressed as the mean difference ± s.e. from the control group. There were 10 calvaria/group. The P values give the significance of the difference from the control group; NS = not significant.
was a tendency towards net calcium
uptake.
These preliminary observations allowed
more meaningful conclusions to be drawn
from the subsequent co-culture studies.
Co-culture experiments
The bone-resorbing activity of several
renal cortical carcinomas is shown in
Table III. In each experiment the bone-
resorbing activity associated with tumour
explants was compared with that of a
maximally effective concentration of PTH
(1 u/ml) and normalized to a constant
PTH effect of 1-5 ,tmol calcium released
in 3 days. Nine of the 13 tumours caused
significant bone resorption, whilst none of
the control renal tissue samples were
effective.
Cyclic AMP levels in pooled media were
less than 2 pmol/ml, even when theo-
phylline was included in incubations, and
immunoreactive PTH levels were less
than 1 ng/ml in all experiments.
In several cases the possibility that a
prostaglandin might have caused bone
resorption was investigated by including
indomethacin (14 /tM) in the culture
medium. Table III shows that this con-
centration of indomethacin did cause a
variable degree of inhibition of tumour-
induced bone resorption, consistent with
a possible role of PGs in bone resorption
caused by these carcinomas.
p
NS
NS
NS
<0-001
<0 001
<0-01
NS
NS
NS
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TABLE III.-The Effect of Control and Tnmour Tissues on Bone in Culture on
Ca Release as pmol/3 dayst
Patient no. Control kidney
1 NT
2 NT
3 NT
4 NT
5 0-02±0-12
6 0-33±0-18
7 0-14±0-14
8 -0-19±0-08
9 NT
10 0 07±0 07
11 0-03±0-06
12 -0-32±0-07
13 0-204-0-15
Tumour
0 524-0 11*
0-69±0- 15*
1.02±0.26*
0 88±0- 18*
1-03±0- 17*
0 52±0 19*
0-58±0.14* 0-29±0-10.
0-02±0-20
0.73±0.20*
0-25±0-08
-0-23±0-11
0-19±0-12
Indomethacin (14 liM)
inhibition of
tumour-induced
resorption
NT
NT
NT
92%
37%
87%
66%
116%
NT
NT
97%
NT
NT
* = significant (P < 0-05) resorption in these co-cultures.
t Expressed as the mean difference ± s.e. between calvaria cultured with renal tissue and control calvaria. NT = not tested.
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In some cases it was found that when
theophylline (1 mM) was included in
culture medium to prevent cyclic AMP
breakdown an enhancement of tumour-
induced resorption occurred. The data are
shown in Table IV. A typical example is
shown in Fig. 2. This was not due to a
direct action of cyclic AMP upon bone,
since no detectable cyclic nucleotide was
found in pooled culture media. Fig. 2 (top)
shows the PGE level in pooled culture
medium from the same experiment.
oJ
Con Tum Tum Tun-. Norm PTH
IDM Theo Kid
FIG. 2.-The effect of various treatments on
tumour-induced bone resorption and PGE
levels in Patient 6. Con, untreated calvaria; Tum, calvaria + tumour; Tum IDM, tumour + 14 j,M indomethacin; Tum +
Theo, tumour + 0-1 mm theophylline; Norm Kid, control kidney; PTH, 1 jug PTH/ml (no tumour). PGE levels refer to
estimates on pooled culture medium from
each group.
Medium from bone co-cultured with
tumour contained significant amounts of
PGE which were reduced by addition of
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TABLE IV. -The Effect of Indomethacin and Theophylline on Thmrnor-induced
Bone Resorption and PGE Levels in (Culture Media
C'alcium release (,umol/3 :lays, n= 1()t _..
1s
Tumotur Tumnour
Ttumotur iiidomethacinl theophylmle
B 0 -052X0-19 0-06 0-03* 1 -24 0.-09*
7 0 58 J0 14 0.23.' 0.06* 0 S9'3 0 (14*
0-29 0 1 00 005±0.07* 0 86 0 15*
2 -0 23±0 11 --0 48+0 12 106 ; 0.32*
* significant (lifference from tuimotur alonie (P 0 05).
t Expressed as the meani (liffereiice + s.c. from the control group.
indomethacin. Of greater interest was the
finding that theophylline caused a, marked
enhancement ofPGE levels, suggesting the
possibility that cyclic AMP may increase
P()r productioni.
Table IV shows other cases in which
PGE levels were measured by radio-
immunoassav. In all cases, medium from
co-culture containe(1 greater amounts of
PGE than culture with bone alone. Levels
were decreased bv indomethacin and
increased bv theophylline.
DISCUSSION
This study demonstrates that fragments
of human renal cortical carcinoma, when
co-cultivated with neonatal mouse bone,
produced bone-resorbing activity. Control
renal cortex did not possess this )roperty.
Several hormones can cause bone resorp-
tion. Prostaglandins (Lee and Attallah,
1975) and 1,25-(OH)2D3 (Lawson et al.,
1971) are produced in normal kidney, and
there is an inicidence, of uinknown fre-
quency, of secretion of PTH by renal
cortical carcinoma (Buckle, McMillan anid
Mallinson, 1970; Greenberg et al., 1973).
Homogenates of renal carcinomas do not
convert 25-hydroxycholecalciferol to 1,25-
(OH)21)3 (Martin et al., 1976). It has also
not been possible to find evidence of PTfl
secretion by the tumours studied in the
present series. This does not exclutde the
possibility that small amounlts ( < I ng/
ml) of the hormone may be secreted in
culture, but muich larger amounts wouldl
be needed to stimulate bone resorptioin.
In other stUidies (1). Atkins, Unpublished
data), co-cultuire of human parathyroid
PGE lev-els in poole(d me(lia (iig/ml)
Ttumouir Ttumour +
Tu-imouir in(lomethacini theophylline
,5 5 0 .038 30-1
3 4 0(55 7 2
6-1 0 62 11t4 4-'3 0 41 78
adenoma tissue with bone leads to resor)-
tioin concomitant with high ( > 0 5 /ig/ml)
levels of immuno-reactive PTH in the
medium. Although PTH production bv
tumours has been reported in association
writh hypercalcaemia (Benson et al., 1974)
it has beeni exclutded as a causative agent in
many other hyperealcaemic patients free
from skeletal metastases (Powell et al.,
1973).
Although cyclie AMP is involved in the
action of PTH on bone (Chase and
Autrbach, 1970), addition oflarge amounts
of exogenous cyclic AMP to bone cultures
(loes not cause bone resorption (Klein and
Raisz, 1 971). Cyclic AMP levels in mediutm-
at the end of the incubatioin period were
undetectable ( < 2 pmol/ml) evein wheni
theophvlline was added. Cyclic AMP
levels were inot estimated at earlier times
or in the bone or tumour tissue. However,
since the dose of theophylline used did
not affect bone per se but did enhance
tumour-induced bone resorption, it is a
strong possibility that cyclic AMP produc-
tion in tumour cells had an effect on the
production of a bone-resorbing factor by
the tumotur cells rather than a direct effect
on bone.
Prostaglandins are potenlt bone-resorb-
itg agents in vitro (Klein and Raisz, 1970)
and are associated, probably as causative
agents, with hypercalcaemia of malig-
nancy (Tashjian et al., 1972; Powles et al.,
1973; Bennett et al., 1975; Dowsett et al.,
1976). Two stuidies have implicated PGs
in the development of hypercalcaemia
associated with renal cortical carcinoma
(Brereton et al., 1974; Robertsoii et al.,
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1975). Evidence that a PG was a cause of
bone resorption in these co-cultured renal
carcinomas comes from the observation
that, to a varying degree, indomethacin
inhibited tumour-induced bone resorp-
tion. Furthermore, indomethacin had no
effect on bone per se or on the response of
bone to other humoral resorbing agents.
In all cases where medium PGE levels
were measured, media from tumour incu-
bations had increased PGE levels which
were lowered by indomethacin treatment.
Although the data strongly suggest that
bone resorption was due to the production
of PGE, the levels of PG found in culture
media were lower than those needed to
obtain substantial bone resorption. How-
ever, if metabolism of PGE occurs in the
culture system, the total amount of PGE
secreted during the 3-day incubation
period may not be accurately represented
by the final concentration. Recently it has
been shown in both man and experimental
animals that the development of hyper-
calcaemia correlates better with PG meta-
bolite levels in plasma and urine (Tashjian,
Koelkel and Levine, 1977b, Seyberth et al.,
1975). Studies are in progress to measure
PGE levels at earlier times and also the
levels of PGE metabolites. Alternatively,
it may well be that PGE does not account
for all the bone-resorbing activity.
Theophylline enhanced tumour-induced
bone resorption and increased PGE levels
in culture media. We suggest that this
may be due, in part, to theophylline
reducing cyclic AMP hydrolysis, in the
face of a high rate of cyclic AMP produc-
tion due to increased membrane adenylate
cyclase activity (Martin et al., 1976).
Jaffe (1974) has previously suggested that
cyclic AMP may enhance PG production
by tumour cells.
It must be stressed that none of our
patients had any overt disorders of
calcium metabolism. Thus this study
demonstrates only the potential for the
production of bone-resorbing factors by
renal cortical carcinomas. However,
Bennett et al. (1975) showed that patients
with breast cancer who produced the
largest amounts of PGs were the most
likely to form bony metastases. In addi-
tion, Galasko and Bennett (1976) showed
that when the VX2 carcinoma was injected
into indomethacin-treated rabbits the
number of bone deposits was reduced. The
present series of renal cortical tumours
has not been followed long enough to
attempt to relate the above observations
to our own.
Although these studies indicate the
ability of renal cortical tumours to
produce prostaglandins as bone-resorbing
agents, the existence of other factors with
similar effects cannot be excluded. In view
of the rapid metabolism of PGE to
metabolites which are less effective onbone
(Atkins and Martin, 1977; Raisz et al.,
1977; Tashjian, Tice and Sides, 1977a) it
may be that PGE production by renal
cortical carcinoma is a major factor in
causing hypercalcaemia only when tumour
has metastasized to bone, or is present as
massive non-bony deposits.
This work was supported by grants from
the Yorkshire Council of the Cancer
Research Campaign and the Medical
Research Council.
REFERENCES
ATKINS, D. & MARTiN, T. J. (1977) Rat Osteogenic
Sarcoma Cells: Effects of some Prostaglandins,
their Metabolites and Analogues on Cyclic AMP
Prodiuction. Prostaglooidios, 13, 561.
ATKINS, D. & PEACOCK, M. (1975) A Comparison of
the Effects of the Calcitonins, Steroid Hormones
an(l Thyroid Hormones oni the Response of Boine
to Parathyroidl Hormone in Tissue Cultture.
J. Eoidocr., 64, 573.
ATKINS, D., ZANELLI, J. M., PEACOCK, Al. & NORDIN,
B. E. C. (1972) The Effect of Oestrogens on the
Response of Bone to Parathyroid Hormone D,
vitro. J. Eodocr., 54, 107.
BENNETT, A., MCDONALD, A. M., SIM-PSON, J. S. &
STAMFORD, 1. F. (1975) Breast, Cancer, Prosta-
glandin, and Bone Metastases. Lancet, i, 1218.
BENSON, R. C., RIIGGS, B. L., PICKARD, B. M. &
ARNAUD, C. D. (1974) Radioimmunoassay of
Parathyioid( Hormone in Hypercalcaemic Patients
with Malignant Disease. Am. J. Med., 56, 821.
BI(GERS, J. D., GWATKIN, R. B. L. & HEYNOR, S.
(1961) Growth of Embryonic Aviaii and Mlam-
malian Tibiae on a Relatively Simple Chemicaliy Defined Medium. Expl. cell Res., 25, 41.
BRERETON, H. D., HALIUSHKA, P. V., ALEXANDER,
R. W., MASON, D. M., KREISER, H. R. & DEVITA,
V. T. (1974) Indomethacin-responsive Hyper-PROSTAGLANDINS FROM CULTURED RENAL CARCINOMA 607
calcaemia in a Patient with Renal Cell Adeno-
carcinoma. New Engl. J. Med., 291, 83.
BROWN, B. L., ALBANO, J. D. M., EKINS, R. P.,
SZHERZI, A. M. & TAMPION, W. (1971) A Simple
and Sensitive Saturation Assay for the Measure-
ment of Adenosine-3' 5'-cyclic Monophosphate.
Biochem. J., 121, 561.
BUCKLE, R. M., MCMILLAN, M. & MALLINSON, C.
(1970) Ectopic Secretion of Parathyroid Hormone
by Renal Adenocarcinoma in a Patient with
Hypercalcaemia. Br. med. J., iv, 724.
CHASE, L. R. & AURBACH, G. D. (1970) The Effect
of Parathyroid Hormone on the Concentration of
Adenosine-3',5-monophosphate in Skeletal Tissues
in vitro. J. biol. Chem., 245, 1520.
DOWSETT, M., EASTY, G. C., POWLES, T. J., EASTY,
D. M. & NEVILLE, A. M. (1976) Human Breast
Tumour-induced Osteolysis and Prostaglandins.
Prostaglandins, 11, 447.
FLOWER, R. J. (1974) Drugs which Inhibit Prosta-
glandin Biosynthesis. Pharm. Rev., 26, 33.
GALASKO, C. S. B. & BENNETT, A. (1976) Relation-
ship of Bone Destruction in Skeletal Metastases
to Osteoclast Activation and Prostaglandins.
Nature, Lond., 263, 508.
GREENBERG, P. B., MARTIN, T. J. & SUTCLIFFE,
H. S. (1973) Synthesis and Release ofParathyroid
Hormone by a Renal Carcinoma in Cell Culture.
Clin. Sci., 45, 183.
HEATH, D. A. (1976) Hypercalcaemia and Malig-
nancy. Ann. clin. Biochem., 13, 555.
HILLIER, K. & DILLEY, S. R. (1974) Separation and
Radioimmunoassay of Foc Prostaglandins using
Silica Gel Micro Columns. Prostaglandins, 5, 137.
JAFFE, B. M. (1974) Prostaglandins and Cancer: An
Update. Prostaglandins, 6, 453.
.KLEIN, D. C. & RAISZ, L. G. (1970) Prostaglandins:
Stimulation of Bone Resorption in Tissue Culture.
Endocrinology, 86, 1436.
KLEIN, D. C. & RAISZ, L. G. (1971) Role of Adeno-
sine-3',5'-monophosphate in the Hormonal Regu-
lation of Bone Resorption: Studies with Cultured
Fetal Bone. Endocrinology, 89, 818.
LAWSON, D. E. M., FRASER, D. R., KODICEK, E.,
MORRIS, H. R. & WILLIAMS, D. H. (1971) Identi-
fication of 1,25-dihydroxycholecalciferol, a New
Kidney Hormone Controlling Calcium Meta-
bolism. Nature, Lond., 230, 228.
LEE, J. B. & ATTALLAH, A. A. (1975) Renal Prosta-
glandins. Nephron, 15, 350.
MARTIN, T. J., HUNT, N. H., BOYD, H., ELLISON,
M., MICHELANGELI, V. P. & ATKINS, D. (1976)
Hormone Receptors and Cyclic Nucleotide
Metabolism in Cancer Cells. Clin. Endocr., 5, 373.
MELICK, R. A. & MARTIN, T. J. (1968) Immunoassay
of Parathyroid Hormone in Human Plasma. In
Parathyroid Hormone and Thyro Calcitonin
Ed. R. V. Talmage. Amsterdam: Excerpta
Medica. p. 440.
MOSELEY, J. M., MARTIN, T. J., ROBINSON, C. J.,
REIT, B. W. & TREGEAR, G. W. (1975). Hormone
metabolism and Response of Adenylate Cyclase to
Parathyroid Hormone in Kidney. Clin. exp.
Pharmac. Phy8iol., 2, 549.
POWELL, D., SINGER, F. R., MURRAY, T. M.
MINKIN, C. & POTTS, J. T., JR. (1973) Non-
parathyroid Humoral Hypercalcaemia in Patients
with Neoplastic Disease. New Enyl. J. Med., 289,
176.
PowIEs, T. J., CLARK, S. A., EASTY, D. M., EASTY,
G. S. & NEVILLE, A. M. (1973) The Inhibition by
Aspirin and Indomethacin of Osteolytic Tumour
Deposits and Hypercalcaemia in Rats with
Walker Tumour, and its Possible Application to
Human Breast Cancer. Br. J. Cancer, 28, 316.
RAISZ, L. G., DIETRICH, J. W., SIMMONS, H. A.,
SEYBERTH, H. W., HUBBARD, W. & OATES, J. A.
(1977) Effect of Prostaglandin Endoperoxide and
Metabolites on Bone Resorption in vitro. Nature,
Lond., 267, 532.
REES, L. H. (1976) The Biosynthesis of Hormones
by Non-endocrine Tumours.-A Review. J.
Endocr., 67, 143.
ROBERTSON, P. R., BAYLINK, D. J., MARINI, J. J. &
ADKINSON, H. W. (1-975) Elevated Prostaglandin
and Suppressed Parathyroid Hormone Associated
with Hypercalcaemia and Renal Cell Carcinoma.
J. clin. Endocr. Metab., 41, 164.
SEYBERTH, H. W., SEGRE, G. V., MORGAN, J. L.,
SWEETMAN, B. J., POTTS, J. T., JR. & OATES, J. A.
(1975) Prostaglandins as Mediators of Hyper-
calcemia Associated with Certain Types of Cancer.
New Engl. J. Med., 293, 1278.
TASHJIAN, A. H., VOELKEL, E. F., LEVINE, L. &
GOLDHABER, P. (1972) Evidence that the Bone-
resorption Stimulating Factor Produced by Mouse
Fibrosarcoma Cells is Prostaglandin E2. J. exp.
Med., 136, 1329.
TASHJIAN, A. H., JR., TICE, J. E. & SIDES, K.
(1977a) Biological Activities of Prostaglandin
Analogues and Metabolites on Bone in Organ
Culture. Nature, Lond., 266, 645.
TASHJIAN, A. H., JR., VOELKEL, E. F. & LEVINE, L.
(1977b) Effects of Hydrocortisone on the Hyper-
calcemia and Plasma Levels of 13, 14-Dihydro-
15-keto-prostaglandin E2 in Mice Bearing the
HSDM1 Fibrosarcoma. Biochem. biophys. Res.
Commun., 74, 199.
WEBSTER, L. A., ATKINS, D. & PEACOCK, M. (1974)
A Bioassay for Parathyroid Hormone using Whole
Mouse Calvaria in Tissue Culture. J. Endocr., 62,
631.